AdaptHealth (AHCO)
(Delayed Data from NSDQ)
$10.79 USD
-0.43 (-3.83%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $10.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.79 USD
-0.43 (-3.83%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $10.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Zacks News
5 Valuable Price-to-Book Stocks to Add to Your Portfolio
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks that have high-growth prospects. ASE Technology Holding (ASX), AdaptHealth Corp. (AHCO), ICL Group (ICL), Conn's (CONN) and Atlas Corp. (ATCO) are some such picks.
Can AdaptHealth (AHCO) Stock Continue to Grow Earnings?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider AdaptHealth (AHCO).
Does AdaptHealth Corp. (AHCO) Have the Potential to Rally 60% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for AdaptHealth Corp. (AHCO) points to a 60% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AHCO or PETQ: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. PETQ: Which Stock Is the Better Value Option?
AdaptHealth Corp. (AHCO) Q3 Earnings Miss Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -41.18% and 2.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AdaptHealth Corp. (AHCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AdaptHealth Corp. (AHCO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -137.93% and 7.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AdaptHealth Corp. (AHCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AdaptHealth Corp. (AHCO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -29.17% and -0.57%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AHCO vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. SYK: Which Stock Is the Better Value Option?
AdaptHealth (AHCO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AdaptHealth (AHCO) has been struggling lately, but the selling pressure may be coming to an end soon
Company News for Mar 5, 2021
by Zacks Equity Research
Companies in The news Are: KR,MEI,AHCO,PRPL
AdaptHealth Corp. (AHCO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of 92.31% and 6.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Enhances Core Business With Buyout
by Zacks Equity Research
Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.
Integra (IART) Acquires Acell, Focuses on Regenerative Space
by Zacks Equity Research
The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.
Globus Medical (GMED) US Spine Grows, Pricing Pressure Stays
by Zacks Equity Research
Globus Medical's (GMED) recent product launches are seeing tremendous uptake.
Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens
by Zacks Equity Research
Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.
PerkinElmer (PKI) Receives FDA EUA for Asymptomatic Testing
by Zacks Equity Research
PerkinElmer's (PKI) RT-PCR assay to test individuals without COVID-19 symptoms acts as prime factor in controlling the spread.
Rockwell Medical (RMTI) Looks Good: Stock Adds 5.9% in Session
by Zacks Equity Research
Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Neogen (NEOG) Launches Dairy Toxin Detection Test Reveal Q+
by Zacks Equity Research
Neogen's (NEOG) new test can detect cancer causing aflatoxin M1 in milk within a range of 150-600 parts per trillion (ppt).
Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax
by Zacks Equity Research
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
Company News for Dec 2, 2020
by Zacks Equity Research
Companies In The News Are: TSLA, KSS, AHCO, XOM
The Zacks Analyst Blog Highlights: PulteGroup, American Water Works, Kinross, AdaptHealth and Procter & Gamble
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PulteGroup, American Water Works, Kinross, AdaptHealth and Procter & Gamble
5 Stocks to Add as Fed Keeps Rates Unchanged
by Tirthankar Chakraborty
We have selected five stocks that are positioned to gain from the Fed's holding of interest rates at an all-time low.
AdaptHealth's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AdaptHealth.